Early Breast Cancer: Making the Difficult Choices
11th International Conference Early Breast Cancer

Faculty

Co-chairs:
          Cliff Hudis, MD
          Martine Piccart-Gebhart, MD, PhD

Speakers:
          Adam Brufsky, MD, PhD
          George Sledge, Jr, MD
          Monica Castiglione, MD
          Angelo Di Leo, MD, PhD
          José Baselga, MD
          David Cameron, MD

Agenda

18.00-18.05 Welcome and Introduction Cliff Hudis, MD
Martine Piccart-Gebhart, MD, PhD
18.00-18.05 Triple-Negative Early Breast Cancer: Is There An Optimal Adjuvant Treatment Strategy? José Baselga, MD
18.05-18.15 Discussion with Faculty All Faculty
18.15-18.20 Taxanes: Are They an Essential Component of Adjuvant Therapy for All Patients Regardless of ER/HER2 Status? Angelo Di Leo, MD, PhD
18.20-18.30 Discussion with Faculty All Faculty
18.30-18.35 Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: Does One Strategy Fit All? Monica Castiglione, MD
18.35-18.45 Discussion with Faculty All Faculty
18.45-18.50 Should Gene Espression Profiles Be Routinely Used OR Are Standard Prognostic Factors Adequate? George Sledge, Jr, MD
18.50-19.00 Discussion with Faculty All Faculty
19.00-19.05 Should Bisphosphonates Now Be Considered as a Component of Adjuvant Therapy for Early Breast Cancer? Adam Brufsky, MD, PhD
19.05-19.15  Discussion with Faculty All Faculty
19.15-19.20 Is There a Patient Profile Where Adjuvant Trastuzumab Is NOT Required Despite HER2 Overexpression? David Cameron, MD
19.20-19.30 Discussion with Faculty All Faculty
  Concluding Remarks Cliff Hudis, MD
Martine Piccart-Gebhart, MD, PhD

Webcast




Support

Support for this program has been provided by an educational grant from: